AirSculpt Technologies, Inc.
AIRSHealthcareNASDAQMedical Care Facilities · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 28
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United. With a market capitalization of $390.8M, it sits in small-cap territory. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure.
Market Cap
$390.8M
Beta
2.02
P/E (TTM)
—
P/E (Fwd)
-277.00
EPS (TTM)
$-0.17
EPS (Fwd)
$-0.02
ROE
-12.6%
ROA
-1.6%
Cash
$16.7M
Total Debt
$71.0M
Free CF
$13.0M
52W Change
25.6%
Annual Financials
Cash vs Debt
On the balance sheet, AIRS has $16.7M in cash with $71.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $13.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -12.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $168.8M (2022) to $151.8M (2025), a 10% decline worth watching.
A beta of 2.02 means AIRS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for AirSculpt Technologies, Inc. and its sector.